• 1
    A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg. 1979; 189: 205-208.
  • 2
    Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 1705-1710.
  • 3
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
  • 4
    Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002; 81: 138-143.
  • 5
    Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 4506.
  • 6
    Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27: 1806-1813.
  • 7
    Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115: 665-672.
  • 8
    Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1017-1021.
  • 9
    Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 678-686.
  • 10
    Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008; 19: 1592-1599.
  • 11
    Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005; 62: 1345-1350.
  • 12
    Arias E, Rostron BL, Tejada-Vera B. United States life tables, 2005. National Vital Statistics Reports. Vol 58, no. 10. Atlanta, GA: National Center for Health Statistics; 2010.
  • 13
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1339-1341.
  • 14
    Chen VK, Arguedas MR, Kilgore ML, Eloubeidi MA. A cost-minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol. 2004; 99: 2223-2234.
    Direct Link:
  • 15
    Wilson LS, Lightwood JM. Pancreatic cancer: total costs and utilization of health services. J Surg Oncol. 1999; 71: 171-181.
  • 16
    Emanuel EJ, Ash A, Yu W, et al. Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med. 2002; 162: 1722-1728.
  • 17
    Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010; 78: 1420-1426.
  • 18
    Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). 2005 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2005: 23( 16S; pt I of II; June 1 suppl). Abstract 4031.
  • 19
    Schellenberg D, Kim J, Columbo L, et al. Phase II trial of single fraction stereotactic body radiotherapy delivered by trilogy linear accelerator for the treatment of locally advanced adenocarcinoma of the pancreas [abstract]. Int J Radiat Oncol Biol Phys. 2008; 72( suppl): S127.
  • 20
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 17 Regs Limited-Use and Hurricane Katrina Impacted Louisiana Cases, November 2008 Submission (1973-2006 varying)—Linked To County Attributes, Total US, 1969-2006 Counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2009, based on the November 2008 submission. [Access date March 13, 2010.]
  • 21
    Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 2002; 27: 121-129.
  • 22
    Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995; 6: 267-274.
  • 23
    Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 211-218.
  • 24
    National Statistics on All Stays 2007. Healthcare Cost and Utilization Project (HCUP) from the US Agency for Healthcare Research and Quality (AHRQ). Washington, DC: AHRQ; 2007. [Access date February 7, 2010.]
  • 25
    Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985; 5: 157-177.
  • 26
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 1637-1641.
  • 27
    Yabroff KR, Schrag D. Challenges and opportunities for use of cost-effectiveness analysis. J Natl Cancer Inst. 2009; 101: 1161-1163.
  • 28
    Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008; 46: 349-356.
  • 29
    Grubbs SS, Grusenmeyer P, Petrelli NJ, Gralla RJ. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? 2006 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2006; 24( 18S; June 20 suppl). Abstract 6048.
  • 30
    Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007; 25: 4506-4507; author reply 4508.
  • 31
    Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011; 34: 63-69.
  • 32
    Ioka T, Nakamura S, Nishiyama K. A randomized phase II study of gemcitabine 1000 mg/m2 and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma [abstract]. Int J Radiat Oncol Biol Phys. 2010; 78( 3 suppl): S102.
  • 33
    Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000; 82: 1783-1788.